Neurocrine Biosciences (NASDAQ: NBIX) CLO exercises 3,349 options shares

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 3,349 shares of common stock on January 8, 2026. The options had an exercise price of $35.99 per share and were originally granted on February 5, 2016, vesting monthly over four years and scheduled to expire on February 5, 2026.

Following the option exercise, Lippoldt directly held 46,754 shares of Neurocrine Biosciences common stock, and the reported incentive stock option position was reduced to zero.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippoldt Darin

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		M		3,349	A	$35.99	46,754	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option	$35.99	01/08/2026		M			3,349	(1)	02/05/2026	Common Stock	3,349	$0	0	D

Explanation of Responses:

1. The option was granted February 5, 2016 and vested monthly over four years. These options were due to expire on February 5, 2026.

Remarks:

	/s/ Darin Lippoldt	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NBIX Chief Legal Officer Darin Lippoldt report?

Darin Lippoldt reported exercising an incentive stock option, acquiring 3,349 shares of Neurocrine Biosciences (NBIX) common stock on January 8, 2026.

At what price were Darin Lippoldt's NBIX stock options exercised?

The incentive stock options were exercised at an exercise price of $35.99 per share, resulting in 3,349 shares of NBIX common stock.

How many Neurocrine Biosciences (NBIX) shares does Darin Lippoldt own after this transaction?

After the reported option exercise, Darin Lippoldt directly owned 46,754 shares of Neurocrine Biosciences common stock.

What was the original grant and expiration schedule of the exercised NBIX options?

The exercised options were granted on February 5, 2016, vested monthly over four years, and were due to expire on February 5, 2026.

Were any derivative securities remaining after Darin Lippoldt’s NBIX option exercise?

Following the transaction, the reported incentive stock option position was reduced to zero derivative securities beneficially owned.

Is Darin Lippoldt a director or officer of Neurocrine Biosciences (NBIX)?

Darin Lippoldt is reported as an officer of Neurocrine Biosciences, serving as its Chief Legal Officer.